Stockholm, Sweden · Founded 2020 · Privately Held (backing)
Developer of antibody technologies intended for cancer, autoimmune diseases, and neurological diseases. AAX Biotech is based in Stockholm, Sweden and was founded in 2020. Its last reported valuation was $4.1 million in Oct 2024. It has raised $1.2 million.
Last reported valuation
$4.1M
Oct 2026
Priced at
—
Total raised
$1.2M
Last round
—
Cap table — not yet on record
AAX Biotech's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of AAX Biotech with a free account
·The complete investor list: 12 names
·Watch AAX Biotech: the Monday email on marks, rounds and moves
